Small doses of subcutaneous insulin as a strategy for preventing slowly progressive β-cell failure in islet cell antibody-positive patients with clinical features of NIDDM

Diabetes

Volumn 45, Issue 5, 1996, Pages 622-626

  Kobayashi, Tetsuro ^a   Nakanishi, Koji ^a   Murase, Toshio ^a   Kosaka, Kinori ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; ISOPHANE INSULIN; PANCREAS ISLET CELL ANTIBODY; SULFONYLUREA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029921391     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.45.5.622     Document Type: Article

References (25)

1. Kobayashi T, Itoh T, Kosaka K, Sato K, Tsuji K: Time course of islet cell antibodies and β-cell function in non-insulin-dependent stage of type 1 diabetes. Diabetes 36:510-517, 1987
2. Kobayashi T, Tamemoto K, Nakanishi K, Kato N, Okubo M, Kajto H, Sugimoto T, Murase T, Kosaka K: Immunogenetic and clinical characterization of slowly progressive IDDM. Diabetes Care 16:780-788, 1993
3. Kobayashi T, Sawano S, Sugimoto T, Itoh T, Kosaka K: Risk factors of slowly progressive insulin-dependent (type 1) diabetes mellitus (Abstract). J Steroid Biochem 20:1488, 1984
4. Kobayashi T, Sawano S, Itoh T, Sugimoto T, Kosaka K, Tanaka T, Suwa K: Slowly progressive IDDM. J Jpn Diabetes Soc 26:1216-1217, 1983
5. Kobayashi T, Nakanishi K, Sugimoto T, Itoh T, Murase T, Kosaka K, Tsuji K: Maleness as risk factor for slowly progressive IDDM. Diabetes Care 12:7-11, 1989
6. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1978
7. Nakanishi K, Kobayashi T, Miyashita H, Okubo M, Sugimoto T, Murase T, Kosaka K, Inouye K, Kono M: Relationships among islet cell antibodies, residual B-cell function, and metabolic control in patients with insulin-dependent diabetes mellitus of long duration: use of sensitive C-peptide radioimmunoassay. Metabolism 39:925-930, 1990
8. Kobayashi T, Sugimoto T, Itoh T, Kosaka K, Tanaka T, Suwa S, Satoh K, Tsuji K: The prevalence of islet cell antibodies in Japanese insulin-dependent and non-insulin-dependent diabetic patients studied by indirect immunofluorescence and by a new method Diabetes 35:335-340, 1986
9. Kawasaki E, Takino H, Yano M, Uotani S, Matsumolo K, Takao Y, Yamaguchi Y, Akazawa S, Nagataki S: Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease Diabetes 43:80-86, 1994
10. Schmidli RS, Colman PG, Bonifacio E. Participating Laboratories: Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies, the Second International GADAb Workshop. Diabetes 44:636-640, 1995
11. Mandrup-Poulsen T, Molvig J, Andersen H, Helqvist S, Spinas GA, Munck M. Canadian-European Randomized Control Trial Group Lack of predictive value of islet cell antibodies, insulin antibodies, and HLA-DR phenotype for remission in cyclosporin-treated IDDM patients. Diabetes 39:204-210, 1990
12. Keller RJ, Eisenbarth GS, Jackson RA: Insulin prophylaxis individuals at high risk of type I diabetes. Lancet 341:927-928, 1993
13. Atkinson MA, Maclaren NK, Luchetta R: Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 39:933-937, 1990
14. Arthur AL, Worcester MA: Insulin injections prevent diabetes (DB) in Biobreeding/Worcester (BB/Wor) rats (Abstract). Diabetes, 35:74A, 1980
15. The DCCT Research Group: Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual β-cell function: observations during eligibility testing for the diabetes control and complications trial (DCCT). J Clin Endocrinol Metab 65:30-36, 1987
16. Shah SC, Malone JI, Maclaren NK, Riley W, Spillar R : High dose insulin therapy (HDIT) resulted in long term survival of beta cells and disappearance of islet cell antibodies (ICA) in IDDM (Abstract). Diabetes 40 (Suppl.):152A, 1991
17. Eizirik DL, Sandler S, Palmer JP. Repair of pancreatic β-cells: a relevant phenomenon in early IDDM? Diabetes 42:1383-1391, 1993
18. Portha B, Picon L. Insulin treatment improves the spontaneous remission of neonatal streptozotocin diabetes in the rat. Diabetes 31:165-169, 1982
19. Vlahos WD, Seemayer TA, Yale JF: Diabetes prevention BB rat inhibition of endogenous insulin secretion. Metabolism 40:825-829, 1991
20. Palmer JP, Helqvist S, Spinas GA: Interaction of β-cell activity and IL-1 concentration and exposure time in isolated rat islet of Langeihans. Diabetes 38:1211-1216, 1989
21. Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL: Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci USA 88:10252-10256, 1991
22. Muir A, Peck A, Clare-Salzer M, Song Y, Cornelius J, Luchetta R, Krischer J, Maclaren N: Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-γ transcription. J Clin Invest 95:628-634, 1995
23. Dupre J, Jenner MR, Mahon JL, Purdon C, Rodger NW, Stiller CR: Endocrine-metabolic function in remission-phase IDDM during administration of cyclosporine. Diabetes 40:598-604, 1991
24. Leslie RDG, Pozzilli P: Type I diabetes masquerading as type II diabetes. Diabetes Care 17:1214-1219, 1994
25. Thai AC, Eisenbarth GS.: Natural history of IDDM. Diabetes Rev 1:1-14, 1993